Positive News SentimentPositive NewsNASDAQ:PRAX Praxis Precision Medicines (PRAX) Stock Price, News & Analysis $334.58 -3.99 (-1.18%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$334.76 +0.18 (+0.05%) As of 09/11/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Praxis Precision Medicines Stock (NASDAQ:PRAX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PRAX alerts:Sign Up Key Stats Today's Range$334.00▼$348.0050-Day Range$291.03▼$386.3352-Week Range$37.24▼$392.70Volume173,532 shsAverage Volume310,168 shsMarket Capitalization$9.34 billionP/E RatioN/ADividend YieldN/APrice Target$585.95Consensus RatingModerate Buy Company Overview Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a biotechnology company focused on developing treatments for central nervous system disorders, including epilepsy, movement disorders and other neurological conditions. The company uses its Precision Genetic Medicine platform, which combines human genetics, functional genomics and neuroscience research to identify disease mechanisms and potential therapeutic targets. Praxis’ pipeline has included investigational medicines such as ulixacaltamide, a treatment candidate being developed for essential tremor, and elsunersen, an antisense oligonucleotide designed for certain severe genetic epilepsies. The company has also evaluated PRAX-628, a next-generation sodium-channel modulator for seizure disorders. These programs are intended to address neurological diseases with significant unmet medical needs. Founded in 2015 and headquartered in Boston, Massachusetts, Praxis conducts research and clinical development activities through collaborations and studies involving patients in multiple regions. The company is led by President and Chief Executive Officer Marcio Souza.AI Generated. May Contain Errors. Read More Praxis Precision Medicines Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScorePRAX MarketRank™: Praxis Precision Medicines scored higher than 61% of companies evaluated by MarketBeat, and ranked 390th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingPraxis Precision Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 3 strong buy ratings, 16 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialPraxis Precision Medicines has a consensus price target of $585.95, representing about 75.1% upside from its current price of $334.58.Amount of Analyst CoveragePraxis Precision Medicines has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Praxis Precision Medicines' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Praxis Precision Medicines are expected to grow in the coming year, from ($13.92) to ($11.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Praxis Precision Medicines is -25.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Praxis Precision Medicines is -25.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPraxis Precision Medicines has a P/B Ratio of 9.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Praxis Precision Medicines' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.81% of the float of Praxis Precision Medicines has been sold short.Short Interest Ratio / Days to CoverPraxis Precision Medicines has a short interest ratio ("days to cover") of 10.16, which indicates bearish sentiment.Change versus previous monthShort interest in Praxis Precision Medicines has recently increased by 0.70%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPraxis Precision Medicines does not currently pay a dividend.Dividend GrowthPraxis Precision Medicines does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment1.60 News SentimentPraxis Precision Medicines has a news sentiment score of 1.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Praxis Precision Medicines this week, compared to 7 articles on an average week.Search InterestOnly 3 people have searched for PRAX on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows8 people have added Praxis Precision Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Praxis Precision Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,611,312.00 in company stock.Percentage Held by Insiders3.00% of the stock of Praxis Precision Medicines is held by insiders.Percentage Held by Institutions67.84% of the stock of Praxis Precision Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Praxis Precision Medicines' insider trading history. Receive PRAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRAX Stock News HeadlinesPraxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)September 12 at 11:00 AM | seekingalpha.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2026 | globenewswire.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 13 at 1:00 AM | Porter & Company (Ad)S&P 500 Futures Drop in Premarket Trading; Praxis Precision Meds, Science Applications LeadAugust 31, 2026 | barrons.comPraxis Precision Medicines Could Be Approaching 'Perfect Trifecta,' Oppenheimer SaysAugust 17, 2026 | finance.yahoo.comRBC Capital Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)August 11, 2026 | theglobeandmail.comIs Praxis (PRAX) Trading Bigger Losses for Long-Run CNS Ambition With Its Cash War Chest?August 8, 2026 | finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Praxis Precision Medicines (PRAX), Charles River Labs (CRL) and Senseonics Holdings (SENS)August 8, 2026 | theglobeandmail.comSee More Headlines PRAX Stock Analysis - Frequently Asked Questions How have PRAX shares performed this year? Praxis Precision Medicines' stock was trading at $294.74 on January 1st, 2026. Since then, PRAX stock has increased by 13.5% and is now trading at $334.58. How were Praxis Precision Medicines' earnings last quarter? Praxis Precision Medicines, Inc. (NASDAQ:PRAX) posted its quarterly earnings results on Thursday, August, 6th. The company reported ($2.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.67) by $0.80. Read the conference call transcript. When did Praxis Precision Medicines' stock split? Praxis Precision Medicines shares reverse split on the morning of Wednesday, November 29th 2023.The 1-15 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Praxis Precision Medicines IPO? Praxis Precision Medicines (PRAX) raised $170 million in an initial public offering on Friday, October 16th 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO and Blackstone Capital Markets was co-manager. Who are Praxis Precision Medicines' major shareholders? Top institutional investors of Praxis Precision Medicines include California State Teachers Retirement System (31.90%), Wellington Management Group LLP (0.45%), Velan Capital Investment Management LP (0.32%) and Bank of New York Mellon Corp (0.31%). Insiders that own company stock include Alex Nemiroff, Lauren Mastrocola and Jill Desimone. View institutional ownership trends. How do I buy shares of Praxis Precision Medicines? Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Praxis Precision Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Praxis Precision Medicines investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings8/06/2026Today9/13/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 PRAX's financial health is in the Green zone, according to TradeSmith. PRAX has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PRAX CIK1689548 Webwww.praxismedicines.com Phone617-300-8460FaxN/AEmployees110Year Founded2015Price Target and Rating Average Price Target for Praxis Precision Medicines$585.95 High Price Target$1,201.00 Low Price Target$83.00 Potential Upside/Downside+75.1%Consensus RatingModerate Buy Rating Score (0-4)2.95 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)($12.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$303.27 million Net MarginsN/A Pretax MarginN/A Return on Equity-34.15% Return on Assets-32.42% Debt Debt-to-Equity RatioN/A Current Ratio15.73 Quick Ratio15.73 Sales & Book Value Annual Sales$8.55 million Price / Sales1,092.57 Cash FlowN/A Price / Cash FlowN/A Book Value$34.85 per share Price / Book9.60Miscellaneous Outstanding Shares27,920,000Free Float27,082,000Market Cap$9.34 billion OptionableOptionable Beta2.76 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:PRAX) was last updated on 9/13/2026 by MarketBeat.com Staff. From Our PartnersA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
